Humacyte rises over 40% on FDA approval for blood vessel implant

Humacyte

20/12/2024 11:04

** Biotech company Humacyte's  HUMA.O  shares rise ~44.2% to
$4.99 premarket
    ** HUMA, late on Thursday, said the U.S. FDA approved its
implant Symvess for patients with extreme blood vessel injury
    ** The approval was based on clinical tests where Symvess
showed high rates of blood flow and low rates of infection 
    ** HUMA says the implant can be used as a channel in
patients who need to have their blood flow restored to avoid
imminent limb loss
    ** Up to last close, stock up 21.8% YTD

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))